US EditionFDA to Offer Faster Drug Reviews to Companies Promoting 'National Priorities'
- U.S. regulators will offer faster reviews for new medicines deemed to promote 'the health interests of Americans' under a new initiative announced on Tuesday.
- FDA Commissioner Marty Makary stated the agency will aim to review select drugs in one to two months.
- The FDA will issue a limited number of 'national priority vouchers' to companies aligned with U.S. national priorities, according to the agency's statement.
- Makary noted the FDA might ease requirements for certain drugs, moving away from needing randomized studies for tracking safety and effectiveness.
Insights by Ground AI
Does this summary seem wrong?
61 Articles
61 Articles
All
Left
6
Center
37
Right
6
MedPage Today+2 Reposted by 2 other sources
FDA to Offer Faster Drug Reviews to Companies Promoting 'National Priorities'
(MedPage Today) -- U.S. regulators will begin offering faster reviews to new medicines that administration officials deem as promoting "the health interests of Americans," under a new initiative announced Tuesday. FDA Commissioner Marty Makary...
·New York, United States
Read Full Article
U.S. regulators will begin offering faster reviews for new drugs that administration officials deem promote "the health interests of Americans," under a new initiative announced Tuesday.
Associated Press News+44 Reposted by 44 other sources
FDA to offer faster drug reviews to companies promoting 'national priorities'
The Food and Drug Administration says it will begin offering faster reviews to new medicines that align with Trump administration priorities for Americans' health.
·United States
Read Full ArticleCoverage Details
Total News Sources61
Leaning Left6Leaning Right6Center37Last UpdatedBias Distribution76% Center
Bias Distribution
- 76% of the sources are Center
76% Center
12%
C 76%
12%
Factuality
To view factuality data please Upgrade to Premium
